[{"indications": "Indications\u00a0suppression of inflammatory and allergic disorders; see also notes\r\nabove; inflammatory bowel disease (section 1.5); asthma (section 3.1 and section 3.2); croup (section 3.1); immunosuppression (section 8.2.2); rheumatic\r\ndisease (section 10.1.2); eye (section 11.4.1); ear (section 12.1.1)", "name": "PREDNISOLONE - GLUCOCORTICOID THERAPY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.3 Corticosteroids", "6.3.2 Glucocorticoid therapy"], "cautions": "Cautions\u00a0\n(From Cautions and contra-indications of corticosteroids: British National Formulary)\nCautions and contra-indications of corticosteroids; also Duchenne\u2019s muscular dystrophy (possible transient rhabdomyolysis\r\nand myoglobinuria following strenuous physical activity)", "side-effects": "Side-effects\u00a0\n(From Side-effects of corticosteroids: British National Formulary)\nSide-effects of corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4258.htm", "doses": ["By mouth, initially, up to 10\u201320\u00a0mg\r\ndaily (severe disease, up to 60\u00a0mg daily), preferably taken in the\r\nmorning after breakfast; can often be reduced within a few days but\r\nmay need to be continued for several weeks or months", "Maintenance, usual range, 2.5\u201315\u00a0mg daily, but higher doses\r\nmay be needed; cushingoid side-effects increasingly likely with doses\r\nabove 7.5\u00a0mg daily", "By intramuscular injection, prednisolone acetate (section 10.1.2.2), 25\u2013100\u00a0mg once or twice\r\nweekly"], "pregnancy": "Pregnancy\u00a0\n(From Pregnancy and breast-feeding: British National Formulary)\nPregnancy and breast-feeding"}, {"indications": "Indications\u00a0eczematous inflammation in otitis externa (see notes\r\nabove)", "name": "PREDNISOLONE SODIUM PHOSPHATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.1 Drugs acting on the ear", "12.1.1 Otitis externa", "Anti-inflammatory preparations", "Corticosteroids", "PREDNISOLONE SODIUM PHOSPHATE"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Prolonged use of topical corticosteroid ear preparations should be avoided.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local sensitivity reactions may occur.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31415.htm", "doses": ["ear, apply 2\u20133 drops every 2\u20133 hours; reduce\r\nfrequency when relief obtained; eye, section 11.4.1"]}, {"indications": "Indications\u00a0ulcerative colitis, and Crohn\u2019s disease;\r\nother indications, see section 6.3.2, see also preparations", "name": "PREDNISOLONE - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.2 Corticosteroids", "PREDNISOLONE"], "cautions": "Cautions\u00a0section 6.3.2; systemic absorption may occur with rectal preparations; prolonged use should be avoided", "side-effects": "Side-effects\u00a0section 6.3.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2182.htm", "doses": ["By mouth, initially 20\u201340\u00a0mg daily (up\r\nto 60\u00a0mg daily in some cases), preferably taken in the morning after\r\nbreakfast; continued until remission occurs, followed by reducing\r\ndoses", "By rectum, see preparations"], "pregnancy": "Pregnancy\u00a0section 6.3.2"}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "PREDNISOLONE Single use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "PREDNISOLONE", "Single use"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5442.htm", "doses": ["Apply every 1\u20132 hours until controlled then reduce frequency", "Name[Minims\u00ae Prednisolone Sodium Phosphate (Bausch & Lomb) ] Eye drops, prednisolone sodium phosphate 0.5%, net price 20 \u00d7 0.5\u00a0mL = \u00a310.41Excipients  include disodium edetate"]}, {"indications": "Indications\u00a0ulcerative colitis, and Crohn\u2019s disease;\r\nother indications, see section 6.3.2, see also preparations", "name": "PREDNISOLONE Rectal preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.2 Corticosteroids", "PREDNISOLONE", "Rectal preparations"], "cautions": "Cautions\u00a0section 6.3.2; systemic absorption may occur with rectal preparations; prolonged use should be avoided", "side-effects": "Side-effects\u00a0section 6.3.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/215614.htm", "doses": ["By mouth, initially 20\u201340\u00a0mg daily (up\r\nto 60\u00a0mg daily in some cases), preferably taken in the morning after\r\nbreakfast; continued until remission occurs, followed by reducing\r\ndoses", "By rectum, see preparations", "Name[Prednisolone (Non-proprietary) ] Rectal foam in aerosol pack, prednisolone 20\u00a0mg (as metasulphobenzoate sodium)/metered\r\napplication, net price 14-application canister with disposable applicators\r\n= \u00a348.00 Excipients  include cetostearyl alcohol, disodium edetate, polysorbate\r\n20, sorbic acidDose\u00a0proctitis and distal ulcerative colitis, 1 metered application\r\n(20\u00a0mg prednisolone) inserted into the rectum once\r\nor twice daily for 2 weeks, continued for further 2 weeks if good\r\nresponse; child not recommended"], "pregnancy": "Pregnancy\u00a0section 6.3.2"}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "PREDNISOLONE - CORTICOSTEROIDS AND OTHER ANTI-INFLAMMATORY PREPARATIONS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "PREDNISOLONE"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5439.htm", "doses": ["Apply every 1\u20132 hours until controlled then reduce frequency"]}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "PREDNISOLONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "PREDNISOLONE"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5439.htm", "doses": ["Apply every 1\u20132 hours until controlled then reduce frequency"]}]